Anti-podocalyxin antibody that targets tumor microenvironment
View Patent ↗The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.
1. A cancer microenvironment-targeting anti-podocalyxin antibody or an antigen-binding fragment thereof, comprising
a heavy chain CDR1 comprising SEQ ID NO: 2,
a heavy chain CDR2 comprising SEQ ID NO: 3,
a heavy chain CDR3 comprising SEQ ID NO: 4,
a light chain CDR1 comprising SEQ ID NO: 5,
a light chain CDR2 comprising SEQ ID NO: 6 and
a light chain CDR3 comprising SEQ ID NO: 7.
2. The cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof according claim 1 , wherein one or more N-linked sugar chains are bound to an Fc region and fucose is not bound to N-acetylglucosamine at a reducing end of the N-linked sugar chains.
3. A pharmaceutical composition comprising, as an active ingredient thereof, the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 1 .
4. A pharmaceutical composition comprising, as an active ingredient thereof, the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 1 to which a substance having an anti-cancer activity has been bound.
5. A nucleic acid encoding the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 1 .
6. A method of treating a subject for cancer, which comprises administering to the subject the pharmaceutical composition as claimed in claim 3 .
7. A method of treating a subject for cancer, which comprises administering to the subject the pharmaceutical composition as claimed in claim 4 .
8. An expression vector comprising the nucleic acid as claimed in claim 5 .
9. A transformant comprising the expression vector as claimed in claim 8 .
10. A method of treating a subject for cancer, which comprises administering to the subject the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 1 .
11. The cancer microenvironment-targeting anti-podocalyxin antibody or the antigen-binding fragment according to claim 1 , wherein the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof comprises (1)
a heavy chain CDR1 comprising SEQ ID NO: 2,
a heavy chain CDR2 comprising SEQ ID NO: 3,
a heavy chain CDR3 comprising SEQ ID NO: 4,
a light chain CDR1 comprising SEQ ID NO: 5,
a light chain CDR2 comprising SEQ ID NO: 6 and
a light chain CDR3 comprising SEQ ID NO: 7 and
(2) (a) a heavy chain having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 10;
(b) a light chain having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 8, or
(c) a heavy chain having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 10 and a light chain having 80% or more identity with the amino acid sequence represented by SEQ ID NO: 8.
12. A nucleic acid encoding any one of the heavy chains and the light chains as claimed in claim 11 .
13. An expression vector comprising the nucleic acid as claimed in claim 12 .
14. A transformant comprising the expression vector as claimed in claim 13 .
15. A pharmaceutical composition comprising, as an active ingredient thereof, the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 11 .
16. A method of treating a subject for cancer, which comprises administering to the subject the pharmaceutical composition as claimed in claim 15 .
17. A pharmaceutical composition comprising, as an active ingredient thereof, the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 11 to which a substance having an anti-cancer activity has been bound.
18. A method of treating a subject for cancer, which comprises administering to the subject the pharmaceutical composition as claimed in claim 17 .
19. A method of treating a subject for cancer, which comprises administering to the subject the cancer microenvironment-targeting anti-podocalyxin antibody or antigen-binding fragment thereof as claimed in claim 11 .